Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Apr 23, 2024 5:58pm
83 Views
Post# 36004116

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I don't know what it takes

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I don't know what it takesYou may recall that I put forward to THTX the possibility of selling a preferred share issue coupled with a smaller amount of common shares to current shareholders. This would have been a clearly superior alternative for THTX and its shareholders. THTX never even looked into it as a possibility despite my suggesting that my firm and others associated with me might well be willing to take down a big piece of it. So, there may well have been other far superior alternatives but perhaps none that would have diluted legacy shareholders thereby giving the board and management the best chance of not being accountable at the next AGM. Clearly, despite my voting for the board last year when I could have fired some of them, they did not trust us to do that again and opted for diluting us into near oblivion to protect themselves. 

Still, you are likely right about IQ and our interests now being aligned but there are some instances where that may not be the case and I would prefer not to take any further chances that such circumstances might arise. For example, if a Quebec based entity were to offer to take the company over in a low ball bid, culd I count on IQ to vote against that? Probably not.
<< Previous
Bullboard Posts
Next >>